Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 13

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 13
---
 purchase Telomir Common Stock at similar terms as the Warrants.

Immediately after
the Merger, the pre-Merger equity holders of Telomir are expected to hold approximately 50% of the outstanding shares of Telomir, on
a non-diluted basis, and the pre-Merger equity holders of TELI are expected to hold approximately 50% of the outstanding shares of Telomir
Common Stock, on non-fully diluted basis. When taking into account the issuance of the Warrants, 41% of the outstanding shares of TELI
Common Stock and the pre-Merger equity holders of TELI are expected to hold approximately 59% of the outstanding shares of Telomir Common
Stock, on a fully-diluted basis

As fully described in the Merger Agreement, the Exchange Ratio formula is based upon the relative values of TELO and TELI, as determined by Moore Financial Consulting, or Moore, as more fully described in the section titled “ The Merger Agreement—Merger Consideration and Exchange Ratio.” As a condition to Closing, on the Effective Time, TELI must hold at least $1 million in either cash, marketable securities or a combination of cash and marketable securities and certain shareholders of TELI will agree to provide $2 million upon FDA acceptance of an Investigational New Drug (IND) application for Telomir-1, and $2 million upon initiation of a Phase 1/2 study. The actual payments of such amounts following the milestones are not a condition to the closing of the Merger. At the Effective Time, TELO’s stockholders will continue to own and hold their existing shares of TELO Common Stock. Following the Merger, TELO’s shares will continue to be listed on the Nasdaq under the symbol “TELO”.

Q: What will happen to TELO if, for any reason, the Merger does not close?

A:If, for any reason, the Merger does not close, the board of directors of TELO (the “TELO Board”) may elect to, among other things, attempt to complete another strategic transaction similar to the Merger.

Q: Why are the two companies proposing to merge?

A:The Merger will result in an alignment of U.S. and non-U.S. rights to Telomir-1 within a single public company structure, thereby simplifying global development and partnership efforts. As a result of the Merger, TELO will own